HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
Sample Articles
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
PRODUCTS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1601
The FDA has approved lemborexant (Dayvigo – Eisai), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. It is the second orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) was the...  read more...
More from issue 1601
Coming Soon
Drugs Past Their Expiration Date
Drugs for Postmenopausal Osteoporosis
Lemborexant (Dayvigo) for Insomnia
Durysta - A Bimatoprost Implant for Glaucoma
Recommend to Your Library  
Previous Issues
© 2020 The Medical Letter, Inc.